



Biotech Daily

Tuesday August 4, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ORTHOCELL UP 10.5%, GENETIC TECHNO DOWN 7%**
- * **MAYNE \$4m FEDERAL-SOUTH AUSTRALIA MANUFACTURING GRANT**
- * **TRAVELER'S SUPPLY TO BUY 50,000 PACKS OF IMMURON TRAVELAN**
- * **CORRECTION: MMJ PHYTOTECH**
- * **MERCHANT REDUCES TO 15% OF POLYNOVO**
- * **CSL CLOSES ABOVE \$100 A SHARE, AGAIN**

MARKET REPORT

The Australian stock market was up 0.33 percent on Tuesday August 4, 2015 with the ASX200 up 18.6 points to 5,697.9 points.

Eighteen of the Biotech Daily Top 40 stocks were up, 10 fell, 10 traded unchanged and two were untraded.

The recently promoted Orthocell was the best, up eight cents or 10.5 percent to 84 cents with 652,848 shares traded.

Optiscan climbed 8.9 percent; Neuren and Tissue Therapies were up more than six percent; Admedus and Biotron rose five percent or more; Oncosil was up 4.2 percent; Ellex and IDT were up more than three percent; Cellmid, Pharmaxis and Starpharma rose more than two percent; Bionomics, CSL, Mesoblast, Sirtex and Universal Biosensors were up more than one percent; with Clinuvel, Cochlear and Psivida up less than one percent.

Genetic Technologies led the falls, down 0.2 cents or 6.9 percent to 2.7 cents with 2.5 million shares traded.

Anteo, Atcor, Medical Developments and Viralytics fell more than four percent; Compumedics and Prana lost more than three percent; Benitec and Resmed shed more than two percent; Impedimed was down 1.7 percent; with Acrux down by 0.7 percent.

MAYNE PHARMA GROUP

Mayne Pharma says it has been awarded a Federal Government manufacturing grant of up to \$4 million conditional on a funding agreement.

Mayne said that the Next Generation Manufacturing Investment Program was set up by the Federal Government in partnership with the Victorian and South Australian State Governments.

The company said the grant would support “the installation of a large-scale, state-of-the-art, fluid bed spray coater” at its Salisbury, South Australia facility.

Mayne said that the total cost of the project was about \$11 million and was expected to be completed in 2017.

The company said that fluid bed processing technology was used to apply various polymers to drug particles to modify the rate of release of the drug when ingested.

Mayne chief executive officer Scott Richards said the grant would allow the company “to accelerate its investment in additional modified-release manufacturing capacity and capability at the Salisbury site”.

“This investment will support the expected growth in currently marketed products, the commercialization of certain pipeline products filed and to be filed with regulatory agencies and potential new products that will be placed into development,” Mr Richards said.

Mr Richards said that in the year to June 30, 2014 Mayne manufactured and exported more than \$US30million of product and that amount was forecast to double in the year to June 30, 2016 “driven largely by sales of modified-release proprietary and generic products into the US”.

“Over the last two years, Mayne Pharma has directed more than 80 percent of its Australian-based research and development spend to the development of advanced oral drug delivery formulations,” Mr Richards said.

Mayne was up one cent or 0.8 percent to \$1.21 with 2.3 million shares traded.

IMMURON

Immuron says the Springfield, Massachusetts-based Traveler’s Supply has agreed to buy a minimum of 50,000 units of Travelan diarrhoea prevention tablets a year.

Immuron said that Traveler’s Supply specialized in travel-related products including insect repellents, clothing treatments, survival equipment, water purification, re-hydration formulas, outdoor survival products, medical dental kits and pet products.

Traveler’s Supply founder and president Jaqueline Dusza said that prior to Travelan “our only defence was to make people aware of the importance of preparedness with a pre-assembled diarrhoea kit or medical kit which included oral rehydration salts and other medications to alleviate the symptoms”.

“Travelan is unique ... because it is the only product you can take before you experience digestive health issues and is clinically shown to maintain digestive health wherever you are,” Ms Dusza said.

Immuron chairman Dr Roger Aston said the contract was “a major endorsement of our master distribution strategy for the US market which maximizes margin without the high level of investment required with a direct field force”.

“It is a testament to our philosophy to market internationally that one US customer can commit to more volume that we currently sell throughout all of Australia,” Dr Aston said.

“Whilst the first order of 15,000 units should be shipped within the next two weeks, we expect this order to be the first of many more,” Dr Aston said.

Immuron was up three cents or 11.1 percent to 30 cents.

MMJ PHYTOTECH

Last night's edition reported that MMJ Phytotech managing director Andreas Gedeon would have a base salary of \$C330,000 but incorrectly converted the Australian dollar value to \$A452,585.

The correct conversion was \$A344,757.

Biotech Daily apologizes unreservedly for the error.

The Monday sub-editor was confused by a large number of US conversions and failed to reset the calculator to Canadian dollars.

MMJ Phytotech fell 13 cents or 22.0 percent to 46 cents with 5.1 million shares traded.

POLYNOVO (FORMERLY CALZADA)

Merchant Funds Management has reduced its substantial share-holding in Polynovo from 66,594,675 shares (16.40%) to 63,135,964 shares (15.09%).

The Perth, Western Australia-based Merchant Capital said that between August 21, 2013 and July 31, 2015 it bought and sold shares, with the most recent trades the sale of 1,775,000 shares for \$141,564 or 7.975 cents a share.

Polynovo was unchanged at 11.5 cents.

CSL

CSL closed at \$100.77 today, up \$1.94 or 1.96 percent on last night's close of \$98.83. According to Commsec Iress data, CSL shares opened at \$99.00, reaching \$100.00 at 10.10am and climbing as high as \$101.13 at 11.56am.

Many trades were 'algorithmic trading' of single or very small parcels of shares.

CSL previously undertook a three-for-one stock split in 2007, when the share price reached \$100 a share (BD: Oct 17, 2007).

CSL chief executive officer Paul Perreault told a teleconference in February 2015 that there was no intention to undertake a second stock-split.